Base Molecular Resonance Technologies Announces Breakthrough in Quantum Resonance Detection

New advancements unlock expanded capabilities and potential applications for the company's detection platform.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Base Molecular Resonance Technologies (BMRT) has announced a transformational leap in its detection capabilities following six months of intensive research and development. The company's engineers discovered new mechanisms that have led to significant improvements in range, precision, and miniaturization of the Base Molecular Resonance platform. These advancements are expected to expand BMRT's strategic and commercial potential across a range of industries, including medical, defense, and homeland security.

Why it matters

BMRT's Base Molecular Resonance technology has the potential to revolutionize fields like cancer diagnostics, public safety, and national security by enabling highly accurate and non-invasive detection of a wide range of substances and threats. The latest advancements could further enhance the platform's capabilities and open up new applications for the technology.

The details

Through experimental validation and enhancements to the underlying physics architecture, BMRT has achieved significant improvements across its detection platform. Key advancements include enhanced precision targeting, improved signal-to-noise ratio, a new hands-free and self-stabilizing design, dynamic directional modulation, extended operational range, and a 3X reduction in system size. These breakthroughs are expected to unlock new use cases and expand BMRT's addressable markets.

  • Over the past six months, BMRT engineers made the discoveries that led to these advancements.
  • BMRT recently completed a successful government-sponsored test at a national test facility.

The players

Base Molecular Resonance Technologies (BMRT)

A company that has discovered a new area of quantum physics utilizing resonant frequencies to detect a wide range of substances, including weapons, explosives, and diseases.

Lee Duke

Co-Founder and President of BMRT.

Robert "Bo" Short

Co-Founder and CEO of BMRT.

Professor Philippe B. Wilson, PhD

Former Director of the Centre for Applied Innovation at York St John University and current President of the Comparative Medicine Council at The Royal Society of Medicine, who has evaluated BMRT's technology.

Charles M. Duke

U.S. Air Force Brigadier General (ret.) and former NASA astronaut, known for being the 10th person and youngest in history to walk on the Moon during the Apollo 16 mission.

Got photos? Submit your photos here. ›

What they’re saying

“The uniqueness of the underlying architecture, combined with the compounding performance gains now being demonstrated, places this work in the category of breakthrough science that has the potential to be Nobel Prize-worthy in its long-term impact.”

— Professor Philippe B. Wilson, PhD (prnewswire.com)

“This is a breakthrough with the potential to reshape how America protects itself at home and abroad.”

— Charles M. Duke, U.S. Air Force Brigadier General (ret.) and former NASA astronaut (prnewswire.com)

What’s next

BMRT is currently integrating these advancements into next-generation prototypes designed for demonstration, pilot deployment, and strategic partner evaluation.

The takeaway

BMRT's latest breakthroughs in its Base Molecular Resonance technology have the potential to significantly expand the platform's capabilities and applications, with far-reaching implications for fields like medical diagnostics, public safety, and national security.